Research Area
Product Type
| GW788388 is a potent, selective, and orally inhibitor of ALK5 with IC50 of 18 nM. | |
| PHA-848125 is a potent, ATP-competitive cyclin A/CDK2 inhibitor with an IC50 of 45 nM. | |
| ARRY-380 is an orally bioavailable, potent, selective, small-molecule tyrosine kinase HER2 inhibitor with an IC50 of 8 nM. | |
| AT-406 is a potent and orally bioavailable IAP (inhibitor of apoptosis protein) inhibitor of XIAP, cIAP1, and cIAP2 proteins with Ki of 66.4, 1.9, and 5.1 nM, respectively. | |
| NVP-BGT226 is a novel dual PI3K/mTOR inhibitor with an IC50 of 1 nM. |
| Olaparib (AZD2281) is a PARP inhibitor with IC50 of 5 and 1 nM for PARP-1 and PARP-2, respectively. | |
| BIBW2992 (Afatinib) is a next generation tyrosine kinase inhibitor (TKI) that irreversibly inhibits EGFR/HER2 kinase with an IC50 of 14 nM for in vitro potency against HER2. | |
| BEZ235 (NVP-BEZ235) is an inhibitor of PI3K and mTOR.p110, IC50<6nM. | |
| Cediranib (AZD2171) is a potent inhibitor of VEGF receptor tyrosine kinases. It inhibited VEGF-stimulated proliferation and KDR phosphorylation with IC50 of 0.4 and 0.5 nM, respectively. | |
| Perifosine is an Akt inhibitor. the antiproliferative properties of perifosine with an IC50 of 0.6–8.9 µM. | |
| AG-014699 (PF-01367338) is a PARP inhibitor (Ki, 1.4 nmol/L). | |
| MDV3100 is androgen-receptor antagonist inhibitor. Highly recommended inhibitor in AR research. | |
| AT9283 is a small molecule a multi-targeted c-ABL, JAK2, Aurora A and B inhibitor with of 4, 1.2, 1.1 and approximate 3 nM for Bcr-Abl(T3151), Jak2 and Jak3, aurora A and B, respectively. | |
| The primary target for Ponatinib (AP24534) is BCR-ABL, an abnormal tyrosine kinase inhibitor with IC50 of 0.37, 2, 1.5, 2.2, 1.1, 1 and 0.24 nM for native pan-BCR-ABL, mutated form, VEGFR2, FGFR1, PDGFRα, mutant FLT3 phosphorylation and LYN. | |
| AZD6244 (Selumetinib) also known as Selumetinib, ARRY142886, AZD-6244 & ARRY-142886 is MEK 1/2 inhibitor with GI50 values ranging from 14 to 50 nm. |